Sign In
Buy IOVA
$4.38
+0.590 (+15.57%)
At Close: Jun 04, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:30pm, Friday, 18'th Apr 2025
SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Is Iovance Biotherapeutics a Millionaire-Maker?
10:05am, Monday, 14'th Apr 2025
Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money.
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
08:09am, Monday, 07'th Apr 2025
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
01:56pm, Saturday, 22'nd Mar 2025
Iovance Biotherapeutics (IOVA -0.28%) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory a
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
11:05am, Saturday, 22'nd Mar 2025
Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 21'st Mar 2025
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
10:15am, Wednesday, 12'th Mar 2025
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
01:01pm, Friday, 28'th Feb 2025
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showe
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
10:46am, Friday, 28'th Feb 2025
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
09:12pm, Thursday, 27'th Feb 2025
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Inter
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
06:25pm, Thursday, 27'th Feb 2025
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
04:01pm, Thursday, 27'th Feb 2025
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M
What's in Store for These 5 Biotech Stocks This Earnings Season?
11:30am, Monday, 24'th Feb 2025
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know
11:05am, Thursday, 20'th Feb 2025
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
My 3 Favorite Stocks to Buy Right Now
07:30am, Thursday, 20'th Feb 2025
If you're struggling to find compelling prospects for your portfolio right now, you're not alone. The market's usual favorites are seemingly out of favor.
